Pfizer signs Indian generic deals
pharmafile | May 21, 2009 | News story | Sales and Marketing | Pfizer, generics
Pfizer has expanded its presence in the generics market with deals that see it licence 75 products from two Indian drug makers.
The company has acquired rights to 15 injectable products from Claris Lifesciences as well as 60 products (55 pills and five injections) from Aurobindo Pharma.
Financial details of the deals are not known but the medicines include antibiotics and anti-infectives, covering disease areas like cardiovascular and central nervous system disorders.
The move follows Pfizer's signing of several deals with Aurobindo to expand its generic portfolio in the US and Europe earlier this year.
Under the terms of those agreements, Pfizer acquired rights to 39 solid oral dose products in the US and 20 in Europe.
The new, expanded agreements with Aurobindo take in 70 emerging markets and Pfizer said it would commercialise the products in phases, "tailoring its approach for different regions".
"The expansion of our product portfolio from this deal provides a foundation for us to commercialise branded generics based on patient needs within specific regions," said Jean-Michel Halfon, president of Pfizer's emerging markets business unit.
The unit was set up this year and has identified six priority markets: China, India, Brazil, Russia, Turkey and Mexico.
Pfizer is presenting the latest agreement, in part at least, as a means of improving access to medicines in poorer countries.
"This deal illustrates the types of innovative partnerships which will help to advance Pfizer's presence in developing markets and enhance access to needed medicines for billions worldwide," Halfon explained.
Pfizer and Aurobindo have also expanded their existing agreements for developed markets, adding products in the US and Europe.
Meanwhile, the Claris deal focuses entirely on products that have lost market exclusivity in developed countries: North America, Europe, Australia and New Zealand.
David Simmons, president and general manager of Pfizer's Established Products Business Unit, said: "These agreements advance our goals to expand our steriles portfolio and provide hospitals and patients with a wide offering of affordable medicines they can trust.
"Pfizer's reputation for high quality and supply reliability is unrivaled in the industry, and this is critical in the area of sterile injectables."
Generics represent a huge commercial opportunity as the pharma sector comes under increasing financial pressure.
Worth around $270 billion in 2006, the off-patent market could top $520 billion in the next three years.
Pfizer's Greenstone business unit already makes generics, with the company's annual global sales of established products sitting at around $10 billion.
Related stories:
Pfizer expands product deal with Indian generic company
March 05, 2009
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …
